[ad_1]
Corona treatment 327 patients completed
In the news on year-end patient drugs now
Beyond Seegene, second classified in the KOSDAQ
The share price of the three Celltrion brothers is widening the range of expectations for the development of the COVID-19 treatment. Celltrion Healthcare (109,700 +1.48) and Celltrion Pharmaceutical (187,000 +8.72) dominated the market capitalization of the KOSDAQ market at # 1 and # 2, and Celltrion maintains the No. 7 position on the KOSPI.
On the 26th, Celltrion closed the market at 329,500 won, down 0.15% from the previous trading day. However, the company soared 9.45% the day before to 330,000 won, and despite being a huge stock with a market capitalization of more than 40 billion won, it was up more than 20% at the time.
Celltrion, Celltrion Healthcare, and Celltrion Pharmaceutical share prices have driven the increase due to expectations for the development of the COVID-19 treatment.
Celltrion said on day 25 that it administered ‘CT-P59’, a corona19 antibody treatment, to 327 patients from global clinical trials, and announced that it would apply for conditional approval after confirming intermediate results from phase 2 clinical trials. administer to patients around the end of this year if approval for early use is obtained from the Ministry of Food and Drug Safety.
Celltrion President Seo Jeong-jin said at the ‘Korea Investment Festival (KIF) 2020’ in October: “We will produce around 1 million corona19 antibody treatments this year and distribute 10,000 of them to Korea.” ”
Earlier in March, the company announced plans to ‘start animal clinical trial in the first half’ → ‘Start phase 1 clinical trial in July’ → ‘Start phase 2 clinical trial in September, commercial production’ → ‘Early approval in December’.
In response, individual investors responded by actively investing in President Seo’s plan, proceeding as scheduled, and both the stock market and KOSDAQ market institutions spilled their sales while making a profit.
As the three Celltrion brothers rise, the market cap ranking also fluctuates. Celltrion Pharmaceutical has risen to second place in KOSDAQ’s market capitalization after 4 months, and Celltrion Healthcare is ranked No.
The top 5 stocks in market capitalization are replaced with new faces every month. + 2.38%) followed by Baton. Seegene (181,200 + 2.03%), whose market capitalization exceeded 8 trillion won, declined by more than 40% in three months.
Copyright Owner © Securities Daily Unauthorized reproduction and redistribution prohibited
